Ipsen Korea’s advanced renal cell carcinoma treatment Carbometyx (cabozantinib) and Boehringer Ingelheim Korea’s Praxbind Injection, a reversal agent for anticoagulant effect of dabigatran, will get insurance benefit from February, the government said.

Ipsen Korea’s advanced renal cell carcinoma treatment Carbometyx 20mg, 40mg, and 60mg

Astellas Pharma Korea renewed the risk-sharing agreement with the government for prostate cancer medicine Xtandi Soft Cap.

The Ministry of Health and Welfare said its health insurance policy review committee confirmed the revised lists of reimbursable drugs and the maximum amounts of reimbursements as of Wednesday.

According to the latest revisions, the ministry set the maximum reimbursement of Carbometyx 20mg, 40mg, and 60mg at 170,450 won ($153.19) under the risk-sharing agreement. Ipsen Korea had obtained approval for Carbometyx as a treatment for patients with advanced renal cell carcinoma who have been previously treated with vascular endothelial growth factor (VEGF)-targeted therapy.

Boehringer Ingelheim’s Praxbind (idarucizumab) made it on the reimbursement list as the company agreed to pay back the excess annual expense of the National Health Insurance Service for the drug, which was priced at 1,174,635 won.

Praxbind is used for an urgent reversal of the anticoagulant effect of Pradaxa Cap when a patient needs urgent surgery or treatment or suffers life-threatening or uncontrollable bleeding.

Astellas Pharma also renewed the risk-sharing agreement for Xtandi, which has been covered by insurance since November 2014.

However, the reimbursement for Xtandi went down to 24,000 won from the previous 28,150 won. Xtandi is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have been treated with a chemotherapy called docetaxel.

pkt77@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>